Market Research Logo

Burns - Pipeline Review, H2 2015

Burns - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Burns - Pipeline Review, H2 2015’, provides an overview of the Burns’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Burns, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burns and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Burns
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Burns and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Burns products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Burns pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Burns
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Burns pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Burns Overview
Therapeutics Development
Pipeline Products for Burns - Overview
Pipeline Products for Burns - Comparative Analysis
Burns - Therapeutics under Development by Companies
Burns - Therapeutics under Investigation by Universities/Institutes
Burns - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Burns - Products under Development by Companies
Burns - Products under Investigation by Universities/Institutes
Burns - Companies Involved in Therapeutics Development
Adocia
AlgiPharma AS
Biogenomics Limited
Birken AG
CytoTools AG
Destiny Pharma Limited
HanAll Biopharma Co., Ltd.
Kuros Biosurgery AG
MediWound Ltd.
Novan, Inc.
Novartis AG
Pherecydes Pharma SA
Phosphagenics Limited
Se-cure Pharmaceuticals Ltd.
Stratatech Corporation
USV Limited
Vida Therapeutics Inc.
Xiber Science GmbH
Burns - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
albumin (human) (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALLO-ASC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biochaperone PDGF-BB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bromelains - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BVS-857 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Dermatology and Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
epidermal growth factor biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HL-156FIB - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMSP-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KUR-212 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody Conjugated for Burns and Wounds - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MP-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OleogelS-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oligomer G for Wounds And Burns - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEP-04 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PP-0121 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PP-1131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SC-106 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Chronic Wounds and Burns - Drug Profile
Product Description
Mechanism of Action
R&D Progress
StrataGraft Skin Tissue - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V-2248 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XF-70 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xib-1302 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Burns - Recent Pipeline Updates
Burns - Dormant Projects
Burns - Discontinued Products
Burns - Product Development Milestones
Featured News & Press Releases
Apr 29, 2015: Poster Presentation Highlighting NexoBrid Awarded Best-in-Category in Wound Care Practice at the American Burn Association 47th Annual Meeting
Apr 21, 2015: MediWound's NexoBrid Highlighted in Presentations at the 2015 American Burn Association 47th Annual Meeting
Apr 20, 2015: MediWound Initiates U.S. Phase 3 Trial With NexoBrid to Treat Severe Burns
Mar 23, 2015: MediWound's NexoBrid Highlighted in a Presentation at the International Conference on Minimally Invasive Medicine
Nov 03, 2014: MediWound Initiates Post-Marketing Study with NexoBrid to Treat Severe Burns in Pediatric Patients
Oct 07, 2014: MediWound's NexoBrid to be Featured at International Society for Burn Injuries 2014
Jul 16, 2014: MediWound Announces NexoBrid Marketing Approval From Israeli Ministry of Health
May 12, 2014: MediWound Completes Recruitment of Commercial Management Team in Europe
May 08, 2014: MediWound Expands Distribution of NexoBrid to Russia Through Agreement With Genfa Medica
Sep 23, 2012: Positive Recommendation for Marketing Authorization from the European Medicines Agency for its innovative drug - NexoBrid
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Burns, H2 2015
Number of Products under Development for Burns - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Burns - Pipeline by Adocia, H2 2015
Burns - Pipeline by AlgiPharma AS, H2 2015
Burns - Pipeline by Biogenomics Limited, H2 2015
Burns - Pipeline by Birken AG, H2 2015
Burns - Pipeline by CytoTools AG, H2 2015
Burns - Pipeline by Destiny Pharma Limited, H2 2015
Burns - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Burns - Pipeline by Kuros Biosurgery AG, H2 2015
Burns - Pipeline by MediWound Ltd., H2 2015
Burns - Pipeline by Novan, Inc., H2 2015
Burns - Pipeline by Novartis AG, H2 2015
Burns - Pipeline by Pherecydes Pharma SA, H2 2015
Burns - Pipeline by Phosphagenics Limited, H2 2015
Burns - Pipeline by Se-cure Pharmaceuticals Ltd., H2 2015
Burns - Pipeline by Stratatech Corporation, H2 2015
Burns - Pipeline by USV Limited, H2 2015
Burns - Pipeline by Vida Therapeutics Inc., H2 2015
Burns - Pipeline by Xiber Science GmbH, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Burns Therapeutics - Recent Pipeline Updates, H2 2015
Burns - Dormant Projects, H2 2015
Burns - Dormant Projects (Contd..1), H2 2015
Burns - Dormant Projects (Contd..2), H2 2015
Burns - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Burns, H2 2015
Number of Products under Development for Burns - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report